Temporal Expression of Apelin/Apelin Receptor in Ischemic Stroke and its Therapeutic Potential

被引:60
作者
Wu, Yili [1 ,2 ,3 ]
Wang, Xin [1 ,3 ]
Zhou, Xuan [1 ,3 ]
Cheng, Baohua [4 ]
Li, Gongying [1 ,3 ]
Bai, Bo [2 ]
机构
[1] Jining Med Univ, Dept Psychiat, Jining, Peoples R China
[2] Jining Med Univ, Collaborat Innovat Ctr Birth Defect Res & Transfo, Jining, Peoples R China
[3] Jining Med Univ, Shandong Key Lab Behav Med, Jining, Peoples R China
[4] Jining Med Univ, Inst Neurobiol, Jining, Peoples R China
基金
中国国家自然科学基金;
关键词
apelin; apelin receptor (APLNR); ischemic stroke; temporal expression; neuroprotection; ENDOPLASMIC-RETICULUM STRESS; REGULATES APELIN EXPRESSION; REPERFUSION INJURY; OXIDATIVE STRESS; MESSENGER-RNA; APJ RECEPTOR; BRAIN-INJURY; PROTECTS; HEART; SITE;
D O I
10.3389/fnmol.2017.00001
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Stroke is one of the leading causes of death and disability worldwide, and ischemic stroke accounts for approximately 87% of cases. Improving post-stroke recovery is a major challenge in stroke treatment. Accumulated evidence indicates that the apelinergic system, consisting of apelin and apelin receptor (APLNR), is temporally dysregulated in ischemic stroke. Moreover, the apelinergic system plays a pivotal role in post-stroke recovery by inhibiting neuronal apoptosis and facilitating angiogenesis through various molecular pathways. In this review article, we summarize the temporal expression of apelin and APLNR in ischemic stroke and the mechanisms of their dysregulation. In addition, the protective role of the apelinergic system in ischemic stroke and the underlying mechanisms of its protective effects are discussed. Furthermore, critical issues in activating the apelinergic system as a potential therapy will also be discussed. The aim of this review article is to shed light on exploiting the activation of the apelinergic system to treat ischemic stroke.
引用
收藏
页数:8
相关论文
共 76 条
[21]   Apelin/APJ signaling in hypoxia-related diseases [J].
He, Lu ;
Xu, Jin ;
Chen, Linxi ;
Li, Lanfang .
CLINICA CHIMICA ACTA, 2015, 451 :191-198
[22]   Molecular and functional characteristics of APJ - Tissue distribution of mRNA and interaction with the endogenous ligand apelin [J].
Hosoya, M ;
Kawamata, Y ;
Fukusumi, S ;
Fujii, R ;
Habata, Y ;
Hinuma, S ;
Kitada, C ;
Honda, S ;
Kurokawa, T ;
Onda, H ;
Nishimura, O ;
Fujino, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (28) :21061-21067
[23]   Apelin-13 protects neurovascular unit against ischemic injuries through the effects of vascular endothelial growth factor [J].
Huang, Chuyi ;
Dai, Chuanfu ;
Gong, Kai ;
Zuo, Huancong ;
Chu, Heling .
NEUROPEPTIDES, 2016, 60 :67-74
[24]   Apelin is transcriptionally regulated by ER stress-induced ATF4 expression via a p38 MAPK-dependent pathway [J].
Jeong, Kwon ;
Oh, Yoojung ;
Kim, Seong-Jin ;
Kim, Hunsung ;
Park, Key-Chung ;
Kim, Sung Soo ;
Ha, Joohun ;
Kang, Insug ;
Choe, Wonchae .
APOPTOSIS, 2014, 19 (09) :1399-1410
[25]   Mechanism underlying the inhibitory effect of Apelin-13 on glucose deprivation-induced autophagy in rat cardiomyocytes [J].
Jiao, Hui ;
Zhang, Zhi ;
Ma, Qinghua ;
Fu, Wei ;
Liu, Zidong .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (03) :797-802
[26]   Development of Potent and Metabolically Stable APJ Ligands with High Therapeutic Potential [J].
Juhl, Cathleen ;
Els-Heindl, Sylvia ;
Schoenauer, Ria ;
Redlich, Gorden ;
Haaf, Erik ;
Wunder, Frank ;
Riedl, Bernd ;
Burkhardt, Nils ;
Beck-Sickinger, Annette G. ;
Bierer, Donald .
CHEMMEDCHEM, 2016, 11 (21) :2378-2384
[27]  
Kalea AZ, 2010, CURR OPIN INVEST DR, V11, P273
[28]   Apelin-13 Protects the Brain Against Ischemic Reperfusion Injury and Cerebral Edema in a Transient Model of Focal Cerebral Ischemia [J].
Khaksari, Mehdi ;
Aboutaleb, Nahid ;
Nasirinezhad, Farinaz ;
Vakili, Abedin ;
Madjd, Zahra .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2012, 48 (01) :201-208
[29]   Apelin-13 exerts antidepressant-like and recognition memory improving activities in stressed rats [J].
Li, E. ;
Deng, Haifeng ;
Wang, Bo ;
Fu, Wan ;
You, Yong ;
Tian, Shaowen .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 (03) :420-430
[30]  
Li HC, 2003, ACTA PHARMACOL SIN, V24, P1131